Figure 2 shows the network plots for the primary outcomes closest to 12 weeks. Network plots for secondary outcomes are reported in the appendix (pp 624–29). Results of the pairwise meta-analyses and related heterogeneity are reported in the appendix (pp 459–71). Results of the network meta-analyses of primary outcomes at 12 weeks are shown in figure 3, Table 1, Table 2, and the appendix (pp 472, 473). Table 1, Table 2 also show the confidence of estimates for every comparison. Figure 4 summarises data for efficacy (in 10 068 children and adolescents and 8131 adults) and tolerability (in 11 018 children and adolescents and 5362 adults).Table 1Effect of ADHD drugs in children and adults at timepoints closest to 12 weeks in terms of efficacy, as rated by clinicians and teachersAtomoxetineBupropionClonidineGuanfacineMethylphenidateModafinilPlaceboChildrenAdultsChildrenAdultsChildrenAdultsChildrenAdultsChildrenAdultsChildrenAdultsChildrenAdultsAmphetaminesClinicians−0·46 (−0·65 to −0·27)*−0·34 (−0·58 to −0·10)*−0·06 (−0·81 to 0·68)†−0·33 (−0·77 to 0·11)*−0·31 (−0·81 to 0·18)*..−0·35 (−0·59 to −0·10)*..−0·24 (−0·44 to −0·05)*−0·29 (−0·54 to −0·05)*−0·39 (−0·67 to −0·12)*−0·94 (−1·43 to −0·46)‡−1·02 (−1·19 to −0·85)‡−0·79 (−0·99 to −0·58)‡Teachers............................AtomoxetineClinicians....0·40 (−0·34 to 1·14)*0·01 (−0·41 to 0·42)*0·15 (−0·33 to 0·63)*..0·11 (−0·09 to 0·32)*..0·22 (0·05 to
